z-logo
Premium
A novel protein glycan biomarker and LCAT activity in metabolic syndrome
Author(s) -
Gruppen Eke G.,
Connelly Margery A.,
Otvos James D.,
Bakker Stephan J.L.,
Dullaart Robin P.F.
Publication year - 2015
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.12481
Subject(s) - medicine , endocrinology , biomarker , serum amyloid a , acute phase protein , inflammation , c reactive protein , cholesterol , metabolic syndrome , lipoprotein , diabetes mellitus , biology , biochemistry
Background The cholesterol‐esterifying enzyme, lecithin:cholesterol acyltransferase ( LCAT ), is instrumental in high‐density lipoprotein ( HDL ) remodelling. LCAT may also modify oxidative and inflammatory processes, as supported by an inverse relationship with HDL antioxidative functionality and a positive relationship with high‐sensitivity C‐reactive protein (hs CRP ). GlycA is a recently developed proton nuclear magnetic resonance ( NMR ) spectroscopy‐measured biomarker of inflammation whose signal originates from a subset of N ‐acetylglucosamine residues on the most abundant glycosylated acute‐phase proteins. Plasma GlycA correlates positively with hs CRP and may predict cardiovascular disease even independent of hs CRP . Here, we tested the extent to which plasma GlycA is elevated in metabolic syndrome (MetS), and determined its relationship with LCAT activity. Materials and methods Plasma GlycA, hs CRP , serum amyloid A ( SAA ), tumour necrosis factor‐α ( TNF ‐α) and LCAT activity were measured in 58 subjects with MetS (including 46 subjects with type 2 diabetes mellitus (T2 DM )) and in 45 nondiabetic subjects without MetS. Results Plasma GlycA was higher in MetS coinciding with higher hs CRP and LCAT activity ( P  <   0·01 for each). In all subjects combined, GlycA was correlated positively with hs CRP , SAA and LCAT activity ( P  <   0·001 for each), but not with TNF ‐α. Age‐ and sex‐adjusted multivariable linear regression analysis revealed that GlycA was positively associated with LCAT activity ( P  =   0·029), independent of the presence of MetS, T2 DM , hs CRP and SAA . GlycA was unrelated to diabetes status. Conclusion A pro‐inflammatory glycoprotein biomarker, GlycA, is higher in MetS. Higher plasma levels of this glycoprotein biomarker relate to increased LCAT activity in the setting of MetS.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here